Aegerion Pharma (AEGR) Misses Q2 EPS by 9c, Sales Beat; Reiterates FY Sales View

Aegerion Pharma (NASDAQ: AEGR) reported Q2 EPS of ($0.37), $0.09 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $64.2 million versus the consensus estimate of $58.98 million.

Company reiterates 2015 total net product sales guidance of between $205 and $235 million

Chief Executive Officer Sandford D. Smith commented, "Aegerion continued to show good progress during the second quarter in key areas of the business, including growth in number of patients on therapy for both of our products. We believe we are on track to deliver strong results; however, as we navigate through the early days of the PCSK9 inhibitor launches, we are maintaining our prior guidance for the year. We remain focused on building a fully integrated, leverageable and risk-diversified company to deliver therapies to patients with rare diseases."

"With the objective of maximizing the value of our current assets, we have focused attention and resources on expanding the opportunities for both MYALEPT and JUXTAPID by prioritizing investments in research and development to support the potential development of a next generation JUXTAPID; planning for a JUXTAPID/PCSK9 inhibitor combination study; and assessing possible expansion into additional indications with MYALEPT. With a financially sound business, we're focused on efforts to create value through these pipeline opportunities and our business development efforts."

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c